• Users Online: 408
  • Print this page
  • Email this page
Year : 2020  |  Volume : 4  |  Issue : 1  |  Page : 3-8

Precision oncology innovation: Sarcoma as an example

Department of Basic Medical Science, Faculty of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia

Correspondence Address:
Dr. Abdul-Mohsen G Alhejaily
Department of Basic Medical Science, Faculty of Medicine, King Fahad Medical City, Riyadh
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jmsr.jmsr_98_19

Rights and Permissions

Patients suffering from cancer will be extensively categorized for gene mutations and other genetic aberrations, and their treatment will uniquely be based on molecular profiling instead of their cancer being initiated or detected in the body. This approach is part of what is called precision medicine (PM). The better molecular understanding of cancer that we are gaining and applying toward the development of new therapies will be applicable to cancer prevention and screening. The field of PM in oncology or precision oncology (PO) is an appropriate choice to begin the initiative of PM. The integration of genomic information from tumors with clinical information, including treatment response and patient outcomes, will create a helpful resource to enhance anticancer therapeutics that are more effective and less toxic than the traditional treatments. Sarcomas are a heterogeneous group of tumors that display a remarkable heterogeneity, with more than 50 subtypes identified so far. Enhancements in the high throughput genomic sequencing have contributed to the discovery of genomic events associated with these heterogeneous tumors and the underlying biology, have opened up paths to discover molecular targeted therapeutics, and improve the clinical decision-making processes. This review will focus on how the integration of the PO approach will affect the drug development in sarcomas and strategies for optimizing finding of novel diagnostic, prognostic, and predictive biomarkers in addition to developing more-effective personalized therapeutic approaches for patients with sarcoma.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded105    
    Comments [Add]    

Recommend this journal